ReviewCardiovascular diabetology. Endocrinology reports2026
The adipomyokine paradox and sex-specific metabolic divergence in subclinical hypothyroidism: a systematic review and meta-analysis.
Review in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubclinical hypothyroidism (SCH) increases CVD risk but the threshold for treatment remains controversial. Sex-based metabolic profiles, novel adipocytokines (Irisin/Apelin), and reversibility of vascular remodeling were examined.
methodsA PRISMA 2020-compliant systematic review of PubMed/MEDLINE, Scopus, and Web of Science was conducted using the PROSPERO-aligned search window from 1 January 2010 to 31 December 2023. Ten studies met the final eligibility criteria and were synthesized according to outcome comparability. Study quality was assessed using RoB 2 and the Newcastle-Ottawa Scale, and certainty of evidence was considered using GRADE principles.
resultsSCH was associated with a pro-atherogenic phenotype, including higher Atherogenic Index of Plasma (AIP) in observational evidence. Sex-specific patterns were observed: cohort evidence suggested increased incident metabolic syndrome among younger men with SCH (HR 1.87; 95% CI: 1.21-2.90), whereas studies in perimenopausal women showed a more lipid-dominant atherogenic profile. Narrative synthesis suggested divergent adipomyokine behavior, with persistent irisin abnormalities despite biochemical euthyroidism and more rapid apelin change in limited interventional evidence. Levothyroxine therapy was associated with modest improvement in selected lipid parameters and CIMT in some interventional studies; however, these findings should not be extrapolated to hard cardiovascular outcomes.
conclusionSCH appears to be associated with heterogeneous cardiometabolic risk patterns across sex, age, adiposity, lipid phenotype, and baseline TSH. The available evidence supports individualized risk assessment but remains insufficient to mandate phenotype-specific treatment thresholds or to infer long-term cardiovascular-risk reduction without further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.